Tekmira Pharmaceuticals Corporation Stock Toronto S.E.
Equities
TKM
CA87911B2093
Pharmaceuticals
Sales 2024 * | 12.63M 9.25M | Sales 2025 * | 13.59M 9.95M | Capitalization | 671M 492M |
---|---|---|---|---|---|
Net income 2024 * | -113M -82.73M | Net income 2025 * | -130M -95.18M | EV / Sales 2024 * | 53.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 49.4 x |
P/E ratio 2024 * |
-6.16
x | P/E ratio 2025 * |
-5.18
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.66% |
Latest transcript on Tekmira Pharmaceuticals Corporation
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 14-06-30 | |
David Hastings
DFI | Director of Finance/CFO | 62 | 18-06-10 |
Karen Sims
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 14-11-30 | |
James Meyers
BRD | Director/Board Member | 58 | 18-10-22 |
Daniel Burgess
BRD | Director/Board Member | 62 | 17-03-22 |
1st Jan change | Capi. | |
---|---|---|
-4.72% | 87.31B | |
+2.63% | 40.86B | |
-21.76% | 29.36B | |
+58.56% | 24.49B | |
-14.78% | 17.31B | |
-18.49% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |